Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2378]

Highlights from ESMO 2019

Prof Josep Tabernero - ESMO President

Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )

SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal...

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC

Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative...

Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO...

Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first...

Dr Thomas Yau - The University of Hong Kong, Hong Kong

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )

Optimal timing of radiotherapy following radical prostatectomy

Prof Chris Parker - The Royal Marsden Hospital, London, UK

Optimal timing of radiotherapy following radical prostatectomy ( Prof Chris Parker - The Royal Marsden Hospital, London, UK )

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with...

Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours ( Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA )

Holistic management of patients with ALK-positive NSCLC

Rachel Thomas and Jackie Fenemore

Holistic management of patients with ALK-positive NSCLC ( Rachel Thomas and Jackie Fenemore )

More from ecancer